AU2013323462A1

AU2013323462A1 - Generation of new pancreatic beta cells

Generation of new pancreatic beta cells Download PDF

Info

Publication number: AU2013323462A1
Authority: AU; Australia
Prior art keywords: seq; peptide; amino acid; antibody; cells
Prior art date: 2012-09-27
Legal status : Abandoned

Application number

AU2013323462A

Other languages

English (en)

Inventor

Claresa LEVETAN

Current Assignee

Individual

Original Assignee

Individual

Priority date

2012-09-27

Filing date

2013-09-26

Publication date

2015-04-23

2012-10-26 Priority claimed from US13/662,253 external-priority patent/US9133440B2/en

2012-10-26 Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en

2012-10-26 Priority claimed from US13/662,245 external-priority patent/US9511110B2/en

2012-10-26 Priority claimed from US13/662,209 external-priority patent/US8911776B2/en

2013-09-26 Application filed by Individual filed Critical Individual

2015-04-23 Publication of AU2013323462A1 publication Critical patent/AU2013323462A1/en

Status Abandoned legal-status Critical Current

Links

210000002237 B-cell of pancreatic islet Anatomy 0.000 title description 11
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 492
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 232
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 227
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 208
241000282414 Homo sapiens Species 0.000 claims abstract description 166
238000000034 method Methods 0.000 claims abstract description 160
239000000816 peptidomimetic Substances 0.000 claims abstract description 114
102000004877 Insulin Human genes 0.000 claims abstract description 113
108090001061 Insulin Proteins 0.000 claims abstract description 113
229940125396 insulin Drugs 0.000 claims abstract description 113
230000004936 stimulating effect Effects 0.000 claims abstract description 102
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 68
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 55
206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 53
208000001280 Prediabetic State Diseases 0.000 claims abstract description 44
201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 44
230000007812 deficiency Effects 0.000 claims abstract description 41
238000012384 transportation and delivery Methods 0.000 claims abstract description 37
206010022489 Insulin Resistance Diseases 0.000 claims abstract description 20
230000004153 glucose metabolism Effects 0.000 claims abstract description 13
102000013405 human Reg receptor Human genes 0.000 claims abstract description 13
108010026315 human Reg receptor Proteins 0.000 claims abstract description 13
230000001771 impaired effect Effects 0.000 claims abstract description 8
102000005962 receptors Human genes 0.000 claims description 227
108020003175 receptors Proteins 0.000 claims description 227
239000003795 chemical substances by application Substances 0.000 claims description 127
206010012601 diabetes mellitus Diseases 0.000 claims description 101
210000004027 cell Anatomy 0.000 claims description 98
150000001413 amino acids Chemical group 0.000 claims description 83
210000000130 stem cell Anatomy 0.000 claims description 72
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 70
239000008103 glucose Substances 0.000 claims description 70
230000027455 binding Effects 0.000 claims description 67
239000000203 mixture Substances 0.000 claims description 52
238000009472 formulation Methods 0.000 claims description 49
235000001014 amino acid Nutrition 0.000 claims description 45
210000000496 pancreas Anatomy 0.000 claims description 33
210000001519 tissue Anatomy 0.000 claims description 32
230000036961 partial effect Effects 0.000 claims description 28
208000013016 Hypoglycemia Diseases 0.000 claims description 25
230000002218 hypoglycaemic effect Effects 0.000 claims description 25
239000000427 antigen Substances 0.000 claims description 24
108091007433 antigens Proteins 0.000 claims description 24
102000036639 antigens Human genes 0.000 claims description 24
108020001507 fusion proteins Proteins 0.000 claims description 24
102000037865 fusion proteins Human genes 0.000 claims description 24
239000013598 vector Substances 0.000 claims description 22
238000007920 subcutaneous administration Methods 0.000 claims description 21
229940079593 drug Drugs 0.000 claims description 20
239000003814 drug Substances 0.000 claims description 20
241000699666 Mus <mouse, genus> Species 0.000 claims description 19
208000008589 Obesity Diseases 0.000 claims description 18
241000283973 Oryctolagus cuniculus Species 0.000 claims description 18
235000020824 obesity Nutrition 0.000 claims description 18
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 17
108010036949 Cyclosporine Proteins 0.000 claims description 17
229960001265 ciclosporin Drugs 0.000 claims description 17
229930182912 cyclosporin Natural products 0.000 claims description 17
241000283690 Bos taurus Species 0.000 claims description 16
241000282577 Pan troglodytes Species 0.000 claims description 16
230000004044 response Effects 0.000 claims description 16
238000001990 intravenous administration Methods 0.000 claims description 15
229960005486 vaccine Drugs 0.000 claims description 15
241001494479 Pecora Species 0.000 claims description 14
210000004185 liver Anatomy 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 14
210000002901 mesenchymal stem cell Anatomy 0.000 claims description 14
210000001185 bone marrow Anatomy 0.000 claims description 13
210000003954 umbilical cord Anatomy 0.000 claims description 13
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 12
201000001421 hyperglycemia Diseases 0.000 claims description 12
229930003316 Vitamin D Natural products 0.000 claims description 11
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
230000002829 reductive effect Effects 0.000 claims description 11
235000019166 vitamin D Nutrition 0.000 claims description 11
239000011710 vitamin D Substances 0.000 claims description 11
150000003710 vitamin D derivatives Chemical class 0.000 claims description 11
229940046008 vitamin d Drugs 0.000 claims description 11
108091022930 Glutamate decarboxylase Proteins 0.000 claims description 10
239000004365 Protease Substances 0.000 claims description 10
108091058544 REG family proteins Proteins 0.000 claims description 10
230000008685 targeting Effects 0.000 claims description 10
208000002705 Glucose Intolerance Diseases 0.000 claims description 9
108091005804 Peptidases Proteins 0.000 claims description 9
230000006735 deficit Effects 0.000 claims description 9
230000004927 fusion Effects 0.000 claims description 9
230000009707 neogenesis Effects 0.000 claims description 9
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 9
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
206010036049 Polycystic ovaries Diseases 0.000 claims description 8
229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 8
235000013922 glutamic acid Nutrition 0.000 claims description 8
239000004220 glutamic acid Substances 0.000 claims description 8
208000006575 hypertriglyceridemia Diseases 0.000 claims description 8
229960003105 metformin Drugs 0.000 claims description 8
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 8
208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
201000010065 polycystic ovary syndrome Diseases 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 8
125000003368 amide group Chemical group 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
229960002109 tuberculosis vaccine Drugs 0.000 claims description 7
210000003606 umbilical vein Anatomy 0.000 claims description 7
102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 6
108010058432 Chaperonin 60 Proteins 0.000 claims description 6
102000006395 Globulins Human genes 0.000 claims description 6
108010044091 Globulins Proteins 0.000 claims description 6
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 6
229940100389 Sulfonylurea Drugs 0.000 claims description 6
239000008186 active pharmaceutical agent Substances 0.000 claims description 6
108700025316 aldesleukin Proteins 0.000 claims description 6
230000005784 autoimmunity Effects 0.000 claims description 6
230000014101 glucose homeostasis Effects 0.000 claims description 6
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 6
229960001243 orlistat Drugs 0.000 claims description 6
229940087463 proleukin Drugs 0.000 claims description 6
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
210000003289 regulatory T cell Anatomy 0.000 claims description 6
238000012216 screening Methods 0.000 claims description 6
229960002930 sirolimus Drugs 0.000 claims description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
102000008214 Glutamate decarboxylase Human genes 0.000 claims description 5
229940123464 Thiazolidinedione Drugs 0.000 claims description 5
230000003247 decreasing effect Effects 0.000 claims description 5
238000001361 intraarterial administration Methods 0.000 claims description 5
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 5
229960004866 mycophenolate mofetil Drugs 0.000 claims description 5
229960004641 rituximab Drugs 0.000 claims description 5
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 4
229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
108010056243 alanylalanine Proteins 0.000 claims description 4
210000001691 amnion Anatomy 0.000 claims description 4
229960002806 daclizumab Drugs 0.000 claims description 4
210000002308 embryonic cell Anatomy 0.000 claims description 4
239000003018 immunosuppressive agent Substances 0.000 claims description 4
210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
108091033319 polynucleotide Proteins 0.000 claims description 4
102000040430 polynucleotide Human genes 0.000 claims description 4
239000002157 polynucleotide Substances 0.000 claims description 4
229960003611 pramlintide Drugs 0.000 claims description 4
108010029667 pramlintide Proteins 0.000 claims description 4
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims description 4
210000002966 serum Anatomy 0.000 claims description 4
210000001988 somatic stem cell Anatomy 0.000 claims description 4
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 3
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 3
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 3
229940123208 Biguanide Drugs 0.000 claims description 3
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 3
229920002905 Colesevelam Polymers 0.000 claims description 3
JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 3
108010008165 Etanercept Proteins 0.000 claims description 3
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 3
108010011459 Exenatide Proteins 0.000 claims description 3
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 3
101000581802 Homo sapiens Lithostathine-1-alpha Proteins 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 3
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 3
LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 3
YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 3
108010019598 Liraglutide Proteins 0.000 claims description 3
241001467552 Mycobacterium bovis BCG Species 0.000 claims description 3
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 3
229960002632 acarbose Drugs 0.000 claims description 3
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
229960002459 alefacept Drugs 0.000 claims description 3
108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
229960004238 anakinra Drugs 0.000 claims description 3
230000001494 anti-thymocyte effect Effects 0.000 claims description 3
229960005347 belatacept Drugs 0.000 claims description 3
229960001713 canagliflozin Drugs 0.000 claims description 3
VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 3
229960001152 colesevelam Drugs 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
229960003834 dapagliflozin Drugs 0.000 claims description 3
229960002061 ergocalciferol Drugs 0.000 claims description 3
229960000403 etanercept Drugs 0.000 claims description 3
229960001519 exenatide Drugs 0.000 claims description 3
210000002767 hepatic artery Anatomy 0.000 claims description 3
102000045287 human REG1A Human genes 0.000 claims description 3
229960003444 immunosuppressant agent Drugs 0.000 claims description 3
239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 3
229960002397 linagliptin Drugs 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
229960002701 liraglutide Drugs 0.000 claims description 3
210000004698 lymphocyte Anatomy 0.000 claims description 3
229950004994 meglitinide Drugs 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
229940099538 rapamune Drugs 0.000 claims description 3
238000007363 ring formation reaction Methods 0.000 claims description 3
QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 3
229960004937 saxagliptin Drugs 0.000 claims description 3
108010033693 saxagliptin Proteins 0.000 claims description 3
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 3
229960004034 sitagliptin Drugs 0.000 claims description 3
235000001892 vitamin D2 Nutrition 0.000 claims description 3
239000011653 vitamin D2 Substances 0.000 claims description 3
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 3
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims description 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
238000003556 assay Methods 0.000 claims description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
230000005847 immunogenicity Effects 0.000 claims description 2
230000004224 protection Effects 0.000 claims description 2
238000007910 systemic administration Methods 0.000 claims description 2
150000003384 small molecules Chemical group 0.000 claims 3
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
238000002965 ELISA Methods 0.000 claims 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
229960002802 bromocriptine Drugs 0.000 claims 1
230000006320 pegylation Effects 0.000 claims 1
210000003240 portal vein Anatomy 0.000 claims 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
101150004107 REG3A gene Proteins 0.000 abstract description 43
238000011282 treatment Methods 0.000 abstract description 31
201000010099 disease Diseases 0.000 abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 abstract description 21
238000002560 therapeutic procedure Methods 0.000 abstract description 20
230000009870 specific binding Effects 0.000 abstract description 15
101150103187 Reg4 gene Proteins 0.000 abstract description 14
230000011664 signaling Effects 0.000 abstract 1
229940024606 amino acid Drugs 0.000 description 131
108090000623 proteins and genes Proteins 0.000 description 72
102000004169 proteins and genes Human genes 0.000 description 50
235000018102 proteins Nutrition 0.000 description 43
101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 description 37
230000006058 immune tolerance Effects 0.000 description 32
230000009467 reduction Effects 0.000 description 32
241000699800 Cricetinae Species 0.000 description 28
230000014509 gene expression Effects 0.000 description 24
230000008929 regeneration Effects 0.000 description 24
238000011069 regeneration method Methods 0.000 description 24
101100189458 Mesocricetus auratus INGAP gene Proteins 0.000 description 22
102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
230000000977 initiatory effect Effects 0.000 description 21
241000124008 Mammalia Species 0.000 description 16
241000700159 Rattus Species 0.000 description 16
108700012369 REG3G Proteins 0.000 description 15
230000000291 postprandial effect Effects 0.000 description 15
239000013604 expression vector Substances 0.000 description 14
235000012054 meals Nutrition 0.000 description 14
125000003275 alpha amino acid group Chemical group 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
150000007523 nucleic acids Chemical group 0.000 description 13
241000282405 Pongo abelii Species 0.000 description 12
101100412401 Rattus norvegicus Reg3a gene Proteins 0.000 description 12
239000012634 fragment Substances 0.000 description 12
210000004408 hybridoma Anatomy 0.000 description 12
241000700199 Cavia porcellus Species 0.000 description 11
108020004414 DNA Proteins 0.000 description 11
241000282578 Gorilla gorilla gorilla Species 0.000 description 11
241000882862 Nomascus leucogenys Species 0.000 description 11
229940125388 beta agonist Drugs 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
230000035935 pregnancy Effects 0.000 description 11
230000002441 reversible effect Effects 0.000 description 11
102000001554 Hemoglobins Human genes 0.000 description 10
108010054147 Hemoglobins Proteins 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 10
241000699673 Mesocricetus auratus Species 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
238000002869 basic local alignment search tool Methods 0.000 description 10
230000000903 blocking effect Effects 0.000 description 10
230000002641 glycemic effect Effects 0.000 description 10
102000018358 immunoglobulin Human genes 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
238000001262 western blot Methods 0.000 description 10
102100024952 Protein CBFA2T1 Human genes 0.000 description 9
241000282898 Sus scrofa Species 0.000 description 9
239000000556 agonist Substances 0.000 description 9
210000004263 induced pluripotent stem cell Anatomy 0.000 description 9
210000004940 nucleus Anatomy 0.000 description 9
239000000902 placebo Substances 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
102000035195 Peptidases Human genes 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
210000000170 cell membrane Anatomy 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000003993 interaction Effects 0.000 description 8
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 8
241001515942 marmosets Species 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
230000005945 translocation Effects 0.000 description 8
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 7
108010075254 C-Peptide Proteins 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000001363 autoimmune Effects 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
210000001671 embryonic stem cell Anatomy 0.000 description 7
239000000284 extract Substances 0.000 description 7
239000000499 gel Substances 0.000 description 7
230000036541 health Effects 0.000 description 7
239000003550 marker Substances 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
238000002483 medication Methods 0.000 description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000009466 transformation Effects 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000006180 TBST buffer Substances 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 6
230000000975 bioactive effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
230000001086 cytosolic effect Effects 0.000 description 6
229940029980 drug used in diabetes Drugs 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
210000004923 pancreatic tissue Anatomy 0.000 description 6
238000010647 peptide synthesis reaction Methods 0.000 description 6
230000007017 scission Effects 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 5
241000282412 Homo Species 0.000 description 5
101001096074 Homo sapiens Regenerating islet-derived protein 4 Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000282341 Mustela putorius furo Species 0.000 description 5
102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 5
108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
210000000805 cytoplasm Anatomy 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
230000028993 immune response Effects 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000004153 islets of langerhan Anatomy 0.000 description 5
238000002823 phage display Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
-1 sulfonylureas Chemical class 0.000 description 5
229950010127 teplizumab Drugs 0.000 description 5
238000013519 translation Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 4
102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
241001529936 Murinae Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000011292 agonist therapy Methods 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
238000004891 communication Methods 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
238000009093 first-line therapy Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
102000049256 human REG3A Human genes 0.000 description 4
230000008004 immune attack Effects 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
150000001467 thiazolidinediones Chemical class 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
101710081722 Antitrypsin Proteins 0.000 description 3
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
102000051325 Glucagon Human genes 0.000 description 3
108060003199 Glucagon Proteins 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
102000002812 Heat-Shock Proteins Human genes 0.000 description 3
108010004889 Heat-Shock Proteins Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000610097 Mesocricetus auratus Pancreatic beta cell growth factor Proteins 0.000 description 3
101000989950 Otolemur crassicaudatus Hemoglobin subunit alpha-A Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
229960003697 abatacept Drugs 0.000 description 3
239000003463 adsorbent Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000001475 anti-trypsic effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000034303 cell budding Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
VGGRNGOEDNBLPH-YJHCMWSWSA-N diapep277 Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 VGGRNGOEDNBLPH-YJHCMWSWSA-N 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
229960004666 glucagon Drugs 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
102000053579 human REG4 Human genes 0.000 description 3
238000003125 immunofluorescent labeling Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
210000000277 pancreatic duct Anatomy 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
230000001172 regenerating effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000000638 solvent extraction Methods 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
241000894007 species Species 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
239000002753 trypsin inhibitor Substances 0.000 description 3
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
101100208110 Arabidopsis thaliana TRX4 gene Proteins 0.000 description 2
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
102000003930 C-Type Lectins Human genes 0.000 description 2
108090000342 C-Type Lectins Proteins 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
101100425276 Dictyostelium discoideum trxD gene Proteins 0.000 description 2
241000289427 Didelphidae Species 0.000 description 2
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
208000005917 Exostoses Diseases 0.000 description 2
241000288988 Galago Species 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
108010014691 Lithostathine Proteins 0.000 description 2
102100027361 Lithostathine-1-alpha Human genes 0.000 description 2
241000282553 Macaca Species 0.000 description 2
208000001145 Metabolic Syndrome Diseases 0.000 description 2
101100154863 Mus musculus Txndc2 gene Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
102000018886 Pancreatic Polypeptide Human genes 0.000 description 2
206010033627 Pancreatic injury Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
101710187074 Serine proteinase inhibitor Proteins 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000002266 amputation Methods 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000001517 counterregulatory effect Effects 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000011124 ex vivo culture Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
239000011536 extraction buffer Substances 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
238000005457 optimization Methods 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
210000002797 pancreatic ductal cell Anatomy 0.000 description 2
230000004203 pancreatic function Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
108010011903 peptide receptors Proteins 0.000 description 2
102000014187 peptide receptors Human genes 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
238000011808 rodent model Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000003001 serine protease inhibitor Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
102100035976 Exostosin-like 3 Human genes 0.000 description 1
101710205521 Exostosin-like 3 Proteins 0.000 description 1
108010020195 FLAG peptide Proteins 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282575 Gorilla Species 0.000 description 1
101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
101710160939 Lithostathine-1-alpha Proteins 0.000 description 1
102100027338 Lithostathine-1-beta Human genes 0.000 description 1
101710180874 Lithostathine-1-beta Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000186366 Mycobacterium bovis Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
102100038553 Neurogenin-3 Human genes 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 1
101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037093 Pruritus genital Diseases 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
102100037889 Regenerating islet-derived protein 4 Human genes 0.000 description 1
102300033249 Regenerating islet-derived protein 4 isoform 1 Human genes 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
101150106167 SOX9 gene Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108700026226 TATA Box Proteins 0.000 description 1
206010043458 Thirst Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000013439 Unusual infection Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
229930189065 blasticidin Natural products 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000007726 cellular glucose metabolism Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000011257 definitive treatment Methods 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960004042 diazoxide Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000003020 exocrine pancreas Anatomy 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000055647 human CSF2RB Human genes 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000008676 import Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000014725 late viral mRNA transcription Effects 0.000 description 1
208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
210000003071 memory t lymphocyte Anatomy 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000027939 micturition Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229950002610 otelixizumab Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000004810 partition chromatography Methods 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001012 protector Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000003751 purification from natural source Methods 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000007306 turnover Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
239000011647 vitamin D3 Substances 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1